Investors Can Find A Compelling Entry Point In NeoGenomics After Recent Weakness

Loading...
Loading...

Shares of NeoGenomics, Inc. NEO have been under significant pressure over the past few months, while the company’s Q3 results reflected “strong execution, steady fundamentals and improved cash positioning – all of which offer potential upside, in our view,” BTIG’s Sean Lavin said in a report. He upgraded the rating on the company from Neutral to Buy, while maintaining the price target at $10.

NeoGenomics’ shares have lost 20 percent over the past few months, due to concerns surrounding a potentially dilutive M&A and integration risk. Although these concerns have not been “entirely allayed,” there are signs of “steady fundamentals and encouraging integration,” analyst Lavin commented.

Q3 Results

NeoGenomics reported its revenue in-line with BTIG’s estimate, although marginally missing consensus expectations. Adj. EBITDA came in higher than expected. While base volume growth was strong, cost per test declined 6 percent, despite management’s focus on the Clarient integration.

Lavin expects “new contract wins and above-average demand in cancer testing to better insulate NEO from broader risk.”

Integration Update

The most important takeaways from management’s integration discussions were “the imminent completion of billing integration and solid salesforce retention, which tend to be the most disruptive factors in lab M&A,” the analyst wrote.

Strong Cash Position

Referring to concerns surrounding the potential for dilutive M&A, Lavin stated that NeoGenomics’ strong cash flow generation has placed the company better to deploy capital. He added, “While we didn’t have a strong opinion on this topic, we view less dilution as a step in the right direction.”

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorLong IdeasUpgradesAnalyst RatingsTrading IdeasbtigSean Lavin
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...